Before the human immunodefi ciency virus/acquired immunodefi ciency syndrome (HIV/AIDS) epidemic, it was estimated that, in the United States, the incidence of anal cancer in men who have sex with men (MSM) is higher than the incidence of cervical cancer in women ( 1 , 2 ) . Current data indicate that the incidence of anal cancer in men has continued to increase ( 3 ) . Infection with human papillomavirus (HPV) is causally linked to the development of anal and cervical cancers and their associated precancerous lesions. Anal squamous intraepithelial lesions (ASILs) are the putative precursors of anal cancer, just as cervical squamous intraepithelial lesions (CSILs) are the precursors of cervical cancer ( 4 -8 ) . ASILs range from low-grade squamous intraepithelial lesions (LSILs) to high-grade squamous intraepithelial lesions (HSILs). We believe that HSILs are the true invasive anal cancer precursors. LSILs are not believed to be a direct precursor to anal cancer but may precede the later development of HSILs ( 7 ) .
Several studies have shown that the detection of cervical cytologic abnormalities (i.e., LSILs and HSILs) is strongly associated with age. Using population-based sampling, Herrero et al. ( 9 , 10 ) demonstrated that the prevalence of LSILs in the cervix peaked at 5.2% among women younger than 25 years, decreased sharply to 2.7% by ages 25 -34 years, and then continued to decrease to 0.4% among women older than 65 years. The prevalence of HSILs in the cervix peaked later, at ages 25 -34 years, and was followed by a less pronounced decline at ages 35 -44 years and a smaller increase in prevalence among women older than 65 years old compared with the increase that was observed at ages 25 -34 years. It has been estimated that cervical HSILs, if undetected, can progress to invasive cervical cancer in 9 -10 years ( 11 ) .
Knowledge of the age-related prevalence and natural history of CSILs has guided the development of screening strategies for cervical cancer, in which women older than 30 years who have had no previously detected lesion may undergo cytology screening at longer than annual intervals because they have a relatively low likelihood of developing a cervical lesion de novo ( 12 , 13 ) . Although several studies have examined the age-associated distribution of CSILs in women ( 9 , 14 ) , and one study has investigated the age-associated prevalence of anal HPV infection in MSM ( 15 ) , no studies have reported the age-associated prevalence of ASILs in MSM or in other populations at high risk for anal cancer. Two studies of ASILs in MSM reported the prevalence, incidence, and risk factors for ASILs for a narrow age spectrum of men living in Seattle ( 16 ) or San Francisco ( 17 ) only. As is the case for CSILs, understanding how age affects the prevalence of ASILs may have implications for anal cytology screening recommendations.
The objectives of this study were to describe the age-related prevalence and risk factors for ASILs in MSM. We also compared the prevalence of ASILs among MSM in four U.S. cities.
We report results of the fi rst study to describe ASILs in a geographically diverse population of HIV-negative MSM spanning a wide age range.
S UBJECTS AND M ETHODS

Study Population
We enrolled men who were concurrently enrolled in four of six EXPLORE trial study cities (Boston, Denver, New York, and San Francisco). The EXPLORE trial is a randomized clinical trial of the effi cacy of a behavioral intervention to reduce the risk of HIV acquisition among sexually active HIV-negative MSM ( 18 -20 ) . Men were eligible for the EXPLORE trial if, at baseline, they were HIV-negative, were 16 years of age or older, and reported having had receptive or insertive anal sex with one or more men during the previous year. Men who had been involved in seroconcordant, monogamous relationships with a male partner for 2 or more years were excluded from the EXPLORE trial. Recruitment strategies for the EXPLORE trial varied slightly among study sites and included advertising and outreach at clubs, bars, bathhouses, sex clubs, health clubs, and video arcades. EXPLORE baseline visits occurred from January 28, 1999, to February 7, 2001 , and subsequent visits were made at 6-month intervals. Enrollment in the HPV substudy was offered to EXPLORE participants in four of six cities after the month 12 EXPLORE study visit. From January 2, 2001 to October 23, 2002 , 1409 men were enrolled in the HPV substudy. At enrollment, each participant provided written informed consent. This study was conducted with the approval of the institutional review boards of each participating center (the University of California at San Francisco; the Department of Public Health at San Francisco, CA and Denver, CO; the New York Blood Center; and the Fenway Community Health Center).
Data Collection
The EXPLORE trial collected information on participants' reported drug use and sexual behaviors with the use of Audio Computer-Assisted Self-Interview (ACASI) technology ( 21 ) that enabled study participants to either hear or read the questions and enter their answers on a keyboard. Both English and Spanish versions of the study questionnaire were available. Compared with interviewer-administered questionnaires, ACASI has been shown to increase the likelihood that sensitive behaviors, such as unprotected anal intercourse, are accurately reported ( 21 ) . We obtained additional data on sexual history and smoking for the HPV substudy by having each participant complete a questionnaire which they then sealed in an envelope after completion for collection . Questionnaires were batched and returned to us by study coordinators.
Anal sample collection and cytology. Trained personnel at each study site collected anal specimens from each study participant by rotating a water-moistened Dacron swab in the anal canal without direct visualization. The swab was then agitated vigorously in a methanol-based fi xative (PreservCyt solution; Cytyc Corporation, Boxborough, MA). The resulting solution was then stored at room temperature and later used for the preparation of thin-layer slides for cytology as well as for the detection of HPV DNA by the polymerase chain reaction (PCR).
Anal cytology was evaluated by a single pathologist (T. Darragh) who had no knowledge of the clinical status of the participants, their questionnaire or ACASI re sponses, or other test results. Anal cytology specimens were classifi ed as normal, atypical squamous cells (ASCs) comprising ASCs of undetermined signifi cance and ASCs that cannot exclude HSILs), LSILs, or HSIL, using the 2001 Bethesda System criteria that are used to evaluate cervical cytology ( 22 ) .
HPV DNA testing. To prepare DNA from the anal specimens, we gently swirled the PreservCyt solutions containing the anal sample to suspend the cells, removed 1.5 mL of the solution to labeled microfuge tubes, and centrifuged the tubes at 16 g for 15 minutes. The supernatants were decanted, and pelleted material was dried overnight at room temperature or for 1 hour at 65 °C. The pellets were resuspended in 100 μ L Sample Transport Medium (Digene, Silver Spring, MD) and 200 μ g/mL proteinase K (Boehringer Mannheim, Indianapolis, IN), mixed by vortexing, incubated for 1 hour at 56 °C in a water bath, heated for 10 minutes at 95 °C for to inactivate the proteinase K, and frozen at − 20 °C.
We used 5 μ L of each sample to detect the presence of one or more HPV types by PCR amplifi cation using a standard 40-cycle protocol, as previously described ( 23 ( 24 , 25 ) .
Statistical Analysis
We used sample proportions to estimate the age-specifi c prevalence of LSILs and HSILs. Independent determinants of ASILs were identifi ed using logistic regression methods. Factors that were statistically signifi cantly associated with ASILs at P <.15 in univariate analyses, as well as those that were identifi ed as being important in previous studies, were retained in the fi nal multivariable models. We used a polytomous logistic regression model to estimate and compare associations with risk factors that distinguished between participants with normal cytology (the referent group) and participants with LSILs and HSILs. The analysis was carried out using Stata software (version 8.0; Stata Corporation, College Station, TX). All statistical tests were two-sided.
R ESULTS
Characteristics of Study Participants at Baseline
Of 1409 participants recruited for this study, samples from 1262 men were suffi cient for cytologic analysis at baseline. Participants had a median age of 37 years (interquartile range [IQR] = 31 -43 years) ( Table 1 ). The median age of participants at fi rst receptive anal intercourse was 20 years (IQR = 17 -24 years). Study participants reported having a median of eight sex partners (IQR = 4 -20) and three receptive anal sex partners (IQR = 0 -11) during the previous 6 months. Men younger than 35 years reported a median of eight sex partners (IQR = 4 -16 partners), men at least 35 years old but younger than 50 years also reported a median of eight sex partners (IQR = 4 -20 partners), and men 50 years of age or older reported a median of 10 partners (IQR = 3 -24 partners) during the previous 6 months. Condoms were always used by 38% of the study participants during the previous 6 months. Participants in San Francisco, New York, Boston, and Denver were similar with respect to median age, other sociodemographic factors, and the median number of receptive anal sex partners they reported having in the previous 6 months (data not shown). There was no statistically signifi cant difference between HPV substudy participants and all enrollees in the EXPLORE trial or between HPV substudy participants with suffi cient cytologic samples and those with insuffi cient samples with respect to age, race, income, sexual behavior, or illicit drug use (data not shown).
Prevalence of ASILs by Age and Geographic Location
The overall prevalence of any abnormal cytology (ASCs, LSILs, or HSILs) in this population was 32% and was similar for all age groups (i.e., a test of trend was not statistically significant). The overall prevalence of ASILs (either LSILs or HSILs) was 20%, and the prevalences of LSILs and HSILs were 15% and 5%, respectively. The prevalences of LSILs and HSILs were similar for all age groups ( Figure 1 ).
The prevalence of ASILs was also similar for all study sites ( Figure 2 ). Cytologic examination revealed that 23% of par ticipants in San Francisco, 19% of participants in New York, 21% of participants in Boston, and 17% of participants in Denver had ASILs ( P = .23 for any differences between cities). Study participants in San Francisco had the highest prevalence of HSILs (8%), followed by those in New York (5%), Boston (4%), and Denver (4%) ( P = .051 for any differences between cities). The prevalences of LSILs and ASCs were similar when stratifi ed by city. 
Risk Factors for ASILs
Variables that were statistically signifi cantly associated with the risk of ASILs in unadjusted analyses included higher number of male receptive anal sex partners in the previous 6 months ( P <.001 for linear trend), any use of poppers (alkyl nitrites) compared with no use in the previous 6 months (OR = 1.6, 95% CI = 1.2 to 2.1, P = .002), use of injection drugs two or more times per month compared with no use in the previous 6 months (OR = 6.7, 95% CI = 1.7 to 27, P = .007), anal HPV infection (OR = 7.5, 95% CI = 4.9 to 11, P <.001), and anal HPV infection with increasing numbers of HPV types ( P <.001 for linear trend) ( Table 2 ). In unadjusted analyses, the risk of ASILs was also statistically signifi cantly associated with infection with highrisk HPV types only (OR = 5.1, 95% CI = 3.1 to 8.4, P <.001), infection with low-risk HPV types only (OR = 9.6, 95% CI = 6.0 to 15, P <.001), and infection with both high-risk and low-risk HPV types (OR = 21, 95% CI = 12 to 35, P <.001) compared with men who were not infected with HPV. However, age, age at fi rst receptive anal intercourse, and smoking status were not associated with ASILs ( P >.10).
We constructed a multivariable logistic model to identify factors associated with ASILs. Because the number of male receptive anal sex partners in the previous 6 months was highly correlated with the number of male sex partners in the previous 6 months ( r >.8), only the number of male receptive anal sex partners variable was used in the fi nal multivariable model. The factors that showed independent, statistically signifi cant associations with ASILs were having more than fi ve receptive anal sex partners compared with fewer than two receptive anal sex partners during the previous 6 months (OR = 1.8, 95% confi dence interval [CI] = 1.1 to 2.8, P = .018), older age at fi rst receptive anal intercourse (OR = 1.3 per 10-year increase in age, 95% CI = 1.0 to 1.7, P = .045), injection drug use two or more times per month compared with no use in the previous 6 months (OR = 17, 95% CI = 1.2 to 223, P =.035), PCR evidence of an anal HPV infection (OR = 2.5, 95% CI = 1.3 to 4.9, P = .008), and anal HPV infection with increasing numbers of HPV types ( P <.001 for linear trend) ( Table 2 ) .
Geographic location remained unassociated with the risk of ASILs in the adjusted model. Although neither age nor smoking status was statistically signifi cantly associated with ASILs in univariate analyses, both factors were included in the fi nal multivariable model because results of previous studies ( 25 ) had indicated that they are important risk factors for anal cancer. Neither factor was statistically signifi cantly associated with the risk of ASILs in the fi nal multivariable model.
Risk Factors for LSILs Compared With Risk Factors for HSILs
Factors that were associated with the risk of LSILs in unadjusted analyses were having more than fi ve male receptive anal sex partners during the previous 6 months compared with having fewer than two receptive anal sex partners (OR = 2.7, 95% CI = 1.8 to 4.0, P = .001), older age at fi rst receptive anal intercourse (OR = 1.3 per 10-year increase in age, 95% CI = 1.02 to 1.5, P = .035), use of poppers during the previous 6 months compared with no use (OR = 1.9, 95% CI = 1.4 to 2.6, P <.001), cocaine use during the previous 6 months compared with no use (OR = 1.3, 95% CI = 1.1 to 2.4, P = .013), use of injection drugs two or more times per month during the previous 6 months compared with no use (OR = 7.5, 95% CI = 1.8 to 31, P = .006), anal HPV infection (OR = 7.6, 95% CI = 4.7 to 12, P <.001), and anal HPV infection with increasing numbers of HPV types ( P <.001 for linear trend) ( Table 3 ). The risk of LSILs was also associated with infection with high-risk HPV types only (OR = 4.6, 95% CI = 2.6 to 8.3, P <.001), with infection with low-risk HPV types only (OR = 11, 95% CI = 6.5 to 18, P <.001), and with infection with both high-risk and low-risk HPV types (OR = 20, 95% CI = 11 to 36, P <.001) compared with men who were not infected with HPV. Factors that showed independent, statistically signifi cant associations with LSILs in a multivariable model were having more than fi ve male receptive anal sex partners during the previous 6 months compared with having fewer than two receptive anal sex partners (OR = 1.9, 95% CI = 1.1 to 3.2, P = .028), older age at fi rst receptive anal intercourse (OR = 1.6 per 10-year age increase, 95% CI = 1.2 to 2.1, P = .004), injection drug use two or more times per month during the previous 6 months (OR = 19, 95% CI =1.3 to 277, P = .03), use of poppers during the previous 6 months (OR = 1.6, 95% CI = 1.1 to 2.5, P = .03), and anal HPV infection with increasing numbers of HPV types ( P <.001 for linear trend) ( Table 3 ). There was suggestive evidence that anal HPV infection, as detected by PCR, may be associated with the risk of LSILs (OR = 2.2, 95% CI = 0.98 to 5.1, P = .056). There was no statistically signifi cant association between age or geographic location and the risk of LSILs in the adjusted model.
Factors that were statistically signifi cantly associated with the risk of HSILs in unadjusted analyses included residence in San Francisco compared with residence in Boston (OR = 0.49, 95% CI = 0.25 to 0.96, P = .04) or Denver (OR = 0.46, 95% CI = 0.22 to 0.98, P = .04), an increasing number of male sex partners ( P = .047 for linear trend); PCR evidence of an anal HPV infection (OR = 7.0, 95% CI = 3.3 to 15, P <.001), and anal HPV infection with increasing numbers of HPV types ( P <.001 for linear trend). The risk of HSILs was also associated with infection with high-risk HPV types only (OR = 6.4, 95% CI = 2.7 to 15, P <.001), infection with both high-risk and low-risk HPV types (OR = 23, 95% CI = 9.6 to 53, P <.001), and infection with low-risk HPV types only (OR = 5.8, 95% CI = 2.3 to 14, P <.001), all compared with no HPV infection. A multivariable logistic model revealed that residence in New York compared with residence in San Francisco (OR = 0.41, 95% CI = 0.17 to 0.98, P = .045), PCR evidence of an anal HPV infection (OR = 3.2, 95% CI = 1.1 to 9.4, P = .039), and anal HPV infection with increasing numbers of HPV types ( P <.001 for linear trend) were independently associated with the risk of HSILs ( Table 3 ) . There was no evidence (i.e., P >.20) for independent associations between age or older age at fi rst receptive anal intercourse and the risk of HSILs. Using a polytomous logistic regression model to compare risk factors for LSILs with those for HSILs, we found that older age at fi rst receptive anal intercourse had statistically signifi cantly different associations with LSILs and HSILs ( P = .012).
D ISCUSSION
Here we report the prevalence of ASILs among HIVnegative MSM, a population that is at an increased risk for the devel opment of invasive anal cancer compared with the general population. We found that a high proportion of sexually active HIV-negative MSM over a wide age range had anal cancer precursor lesions as determined by anal cytology. Given that a previous study showed that anal cytology has only 50% sensitivity for diagnosing HSILs in HIV-negative MSM compared with the gold standard anal biopsy ( 26 ) , the true prevalence of HSILs is likely to be even higher than what we report here. The substantial prevalence of anal HSILs, in particular, places a high proportion of MSM at risk for anal cancer. The overall prevalence of ASILs by cytology was 20% and was similar across all age groups.
Several studies have demonstrated that, among women, the prevalence of cervical HPV infection and subsequent CSILs are strongly associated with age ( 9 , 14 ) . Women may acquire HPV infection at the onset of sexual activity, typically during late adolescence or during their early 20s. Most of these HPV infections are thought to resolve spontaneously. However, a small proportion of women have a persistent HPV infection that leads to CSILs, the incidence of which typically peaks 2 -3 years after the initiation of sexual activity and then drops substantially among older women. An age-related decline in the prevalence of cervical HPV infection has been observed even among high-risk populations, such as female sex workers in Spain ( 27 ) and Mexico City ( 28 ) , as well as among sexually active inner-city women in New York ( 29 ) . By contrast, in the cohort of urban HIV-negative MSM that were recruited for this study, we previously demonstrated that anal HPV infection was not related to age, that anal HPV infection was found in 57% of participants, and that there was no age-related decrease in the prevalence of anal HPV infection ( 15 ) . Consistent with this fi nding is the lack of any age-related decrease in the prevalence of anal cytologic abnormalities, in sharp contrast with what has been observed for CSILs in women.
A number of factors could contribute to differences between the age associations of epidemiology of CSILs in women and that of ASILs in MSM. Although the cervix and the anus are histologically similar, they exist in different hormonal milieus, and the hormonal milieu of the cervix varies with age and menopausal status. However, a more likely explanation for the differences in age associations between the epidemiology of CSILs in women and that of ASILs in MSM is differences in the levels of sexual activity among women in the previous studies and the MSM in our study. The MSM in our study reported having a median of eight male sexual partners during the previous 6 months, a number that remained relatively constant for all age groups, but is substantially greater than the number of new sexual partners reported by most women older than 30 years. For example, behavioral data reported in previous cervical HPV epidemiologic studies show that sexual activity ranged from greater than 50% of subjects having one lifetime sexual partner in a population-based study of cervical dysplasia in Costa Rica ( 9 ) to means of 2.2 sexual partners during the previous year among women 30 to 39 years old and 1.4 sexual partners during the previous year among women older than 40 years in a study of cervical HPV infection among a group of inner-city women in New York ( 29 ) . Studies of cervical HPV in sex workers in Mexico and Spain reported high numbers of sexual partners ( 27 , 28 ) but did not report the age-associated prevalence of cervical cytologic ab normalities and thus cannot be directly compared with our study.
Most of the men in our study had never been screened for ASILs before study entry. It was therefore interesting that the prevalence of LSILs and HSILs did not increase substantially with age because in the absence of screening and subsequent treatment of disease, we would expect an increasing proportion of men to develop ASILs in the older age groups. The fact that we did not observe a cumulative increase in the proportion of MSM with anal cytologic changes with increasing age suggests that many of the lesions that develop after HPV infection are transient. Consistent with this interpretation, we previously reported that the prevalence of anal HPV infection was consistent across all age groups ( 15 ) and was not cumulative. Our observation that older age at fi rst receptive anal sex was associated with the risk of LSILs also suggests that many HPV lesions are transient in nature. If HPV lesions were transient, men who were younger at the time of their fi rst sexual experience were probably exposed to HPV and then developed LSILs that regressed over time. Another, less likely, explanation for this fi nding would be a cohort effect: Older MSM could have been more sexually active and more intensely exposed to HPV than younger MSM in this prevalence study. The 20% prevalence of ASILs in the older men could therefore refl ect a true age-related decrease in the prevalence of ASILs if that particular cohort of men had a substantially higher prevalence of ASILs during their 20s and 30s.
There was no difference in the overall prevalence of ASILs by geographic location. However, there was some evidence that location was a risk factor for HSILs, but not for LSILs. San Francisco had the highest prevalence of HSILs, at 8%, whereas the other sites each had an HSIL prevalence of approximately 4%. The reasons for this difference in prevalence, if it is a true difference, are not immediately apparent but may refl ect differences in behaviors that were not captured by our questionnaire. This possible regional difference in the prevalence of HSILs should be explored in future population-based studies.
As has been seen previously ( 30 , 31 ) , anal HPV infection and the number of HPV types were important risk factors for anal lesions in our study. The strong association between anal HPV infection and ASILs that we found is consistent with the established role of HPV infection in the development of anal cancer ( 4 , 25 ) . Infection with multiple HPV types may be a marker of persistent disease and of the progression of LSILs to HSILs ( 7 ) . At present, there is little evidence that direct molecular interactions among different HPV types potentiate disease pathogenesis, but having multiple HPV types may represent an unmeasured factor(s) that is important in ASIL pathogenesis, such as attenuated HPV-specifi c immunity. Infection with a greater number of HPV types may also result from having a larger number of sexual encounters, which could potentially increase exposure to other unmeasured risk factors associated with anal intercourse, such as infl ammation. Finally, infection with a greater number of HPV types may also refl ect a greater number of lesions, which would increase the probability that an abnormality would be detected by anal cytology.
Previous studies have demonstrated that HPV type (i.e., highrisk versus low-risk) is associated with the type of lesions that later develop ( 24 , 25 ) . Compared with men in whom no HPV DNA was detected, men infected with low-risk HPV types only as well as men infected with high-risk HPV types only had an increased risk of LSILs. Similarly, men who were infected with low-risk HPV types only or with high-risk HPV types only had an increased risk of HSILs compared with men with no HPV infection. Given that earlier studies reported that only high-risk HPV types are closely linked with the development of invasive cervical and anal cancers [reviewed in ( 25 ) ], it is interesting to note that low-risk HPV types were also associated with the risk of HSILs in our study population. However, we found that infection with both high-risk and low-risk HPV types was more strongly associated with either LSILs or HSILs than infection with either high-risk or low-risk HPV types only, consistent with our observation that an increasing number of HPV types is an important risk factor for ASILs. Longitudinal studies that examine the temporal association between type-specifi c HPV infection and progression of ASILs are needed to clarify the relation ship between infection with specifi c HPV types and the risk of incident and persistent HSILs.
Behavioral determinants that were strongly associated with the risk of ASILs included the number of male sex partners during the previous 6 months and the number of receptive anal sex partners during the previous 6 months. These behavioral risk factors for ASILs are not surprising, given the strong evidence for the role of sexual transmission of HPV as a necessary step for development of anal cancer precursor lesions ( 4 ) . We also found evidence for the independent association of injection drug use and use of poppers with the risk of ASILs. A high prevalence of ASILs and anal HPV infection was previously reported among HIV-infected injection drug users who denied having anal intercourse ( 32 ) . The roles of injection drug use and the use of poppers in the pathogenesis of ASILs is unclear; however, the use of such substances may be a proxy for partner selection or for risk behaviors that were not captured in our structured questionnaire.
Strengths of our study include the large number, geographic diversity, and wide age spectrum of the participants. One limitation of our study is that study participants of all ages remained sexually active, with multiple partners. Thus, it is possible that our results are not generalizable to all HIV-negative MSM. However, data collected by the probability-based Urban Men's Health Study ( 33 ) on the sexual behavior of predominantly HIV-negative MSM in four cities (San Francisco, Los Angeles, New York, and Chicago) suggest that the men in our study are highly representative of urban MSM with respect to age at fi rst anal intercourse, any history of anal sex, and history of anal sex during the previous year. Multiple recent cross-sectional surveys of mostly HIV-uninfected MSM in San Francisco ( 34 ) , London ( 35 ) , and Amsterdam ( 36 ) also report sexual behavior similar to that of the men in our study. Thus, although participants in our study are likely to be representative of many urban HIV-negative MSM, future studies that use probability-based sampling are needed before these fi ndings can be generalized to all MSM, particularly to those who have fewer sexual partners than reported by participants in this study. Another possible limitation of our study is the fact that only one pathologist reviewed all of the cytology. (17) 1.00
1.00
29 (9) 1.00 Moreover, any potential under-or overdiagnosis of ASILs would probably affect only our prevalence estimates, not the estimates of associations with potential risk factors. However, the pathologist who interpreted the slides for this study participated in a study of interobserver variability in anal cytology, which showed moderately good interobserver agreement ( κ = 0.55 − 0.88) for anal cytology between experienced pathologists (T. Darragh, personal communication).
Our data indicate that a high proportion of sexually active HIVnegative MSM in all age groups have ASILs, including HSILs. The high prevalence of ASILs may have direct implications for anal cancer screening. Given the similarities between cervical cancer and anal cancer and given the success of cervical cancer screening in reducing mortality, Palefsky et al. ( 26 ) have proposed an anal cytology screening protocol to identify women and men who may have anal cancer precursor lesions. Results of cost-effectiveness analyses indicate that a reasonable screening interval is 2 -3 years for HIV-negative MSM ( 37 ) . It has been further suggested that patients who have an abnormal anal cytology (i.e., Pap) test should undergo high-resolution anoscopy, which uses magnifi cation and characteristic changes in appearance of diseased tissue after the application of acetic acid to identify lesions that should undergo biopsy and staging. Various treatment options that are based on the grade, size, and location of these lesions have been described ( 38 ) . Given that anal cancer occurs only rarely in HIV-negative men aged younger than 40 years, one approach would be to initiate screening only among men older than 40 years. In addition, although the role of anal HPV testing to identify MSM who are at risk for anal cancer has not been fully explored, its primary use may rest in its negative predictive value.
Our study illustrates that the epidemiology of anal cancer precursor lesions in sexually active HIV-negative MSM is different from that of cervical cancer precursor lesions in sexually active women. The high prevalence of HPV-related anal disease at all age groups refl ects a population that continues to have a large number of new sexual exposures over many decades of life. In contrast, the prevalence of HPV-related cervical disease in women is lower and declines with age. Extrapolations from the cervical cancer prevention literature to anal cancer screening cannot be made blindly. Specifi c knowledge of anal HPV and ASIL epidemiology is even more relevant today as advances continue to be made in the therapy of ASILs ( 39 ) , as well as in HPV-specifi c therapeutic ( 40 ) and prophylactic ( 41 ) vaccines.
